BioPharmaPT
← All reports

Novartis AG — Votrient EMA EPAR public assessment report (EMEA/H/C/001141, 2010)

Novartis AG · 2010 · EMA EPAR public assessment report · company profile →

Report summary

This report summarizes the EMA's assessment of Votrient (pazopanib) for advanced renal cell carcinoma (RCC). Preclinical studies demonstrated pazopanib's anti-tumor activity, but also highlighted genotoxicity, embryotoxicity, and teratogenicity. Clinical pharmacology revealed non-linear pharmacokinetics and drug interactions. The pivotal Phase III study (VEG105192) showed significant improvement in progression-free survival and overall response rate compared to placebo in both treatment-naïve and cytokine-pretreated patients. Key safety concerns included hepatic dysfunction, hemorrhage, GI perforation, cardiac events, and hypertension. The CHMP recommended conditional marketing authorization, citing a positive benefit-risk balance, with post-marketing studies required for direct comparison against sunitinib. The approved indication is for first-line treatment and for patients who received prior cytokine therapy, at 800 mg once daily.

Key findings — cited to the page

hypertension (any grade)38 % · p.73
vomiting (any grade)15 % · p.73
elevated aspartate aminotransferase (any grade)12 % · p.73
hair colour change (any grade)39 % · p.73
fatigue (any grade)24 % · p.73
anorexia (any grade)21 % · p.73
dysgeusia (any grade)16 % · p.73
elevated alanine aminotransferase (any grade)14 % · p.73
abdominal pain (any grade)10 % · p.73
diarrhoea (any grade)49 % · p.73
nausea (any grade)27 % · p.73
median PFS (VEG102616, IRC, adjusted for placebo)11.9 monthsVEG102616 · p.50

Source: Novartis AG · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Novartis AG — Votrient EMA EPAR public assessment report (EMEA/H/C/001141, 2010) — Summary & Key Findings | BioPharmaPT